Details of the Drug Pharmacogenomic Perturbation Atlas

Flupentixol Drug Info

2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum

Therapeutic Class

Antipsychotic Neuroleptic drug

Cross-matching ID

PubChem CID

5281881

ChEBI ID

CHEMBL54661

CAS Number

CAS 2709-56-0

VARIDT Drug ID

DR01298

General Information of Drug (ID: DM0DJ9O)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.74	0.00e+0	19/20 (95%)	MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis	2.16	0.00e+0	18/22 (81.82%)	HMGCS1;IDI1;FDPS;...
Steroid hormone biosynthesis	2.14	0.00e+0	43/61 (70.49%)	AKR1C3;HSD17B7;CYP1B1;...
PPAR signaling pathway	2.04	0.00e+0	66/74 (89.19%)	HMGCS1;SCD;FABP7;...
Metabolism of xenobiotics by cytochrome P450	2.01	0.00e+0	49/77 (63.64%)	CYP1B1;AKR7A2;GSTA1;...
Histidine metabolism	1.93	4.13e-3	16/22 (72.73%)	HAL;ALDH2;ALDH3A1;...
Fatty acid biosynthesis	1.92	3.54e-3	16/18 (88.89%)	ACSL4;FASN;ACSL1;...
Biosynthesis of unsaturated fatty acids	1.88	4.13e-3	21/27 (77.78%)	SCD;FADS1;FADS2;...
beta-Alanine metabolism	1.87	5.51e-3	25/30 (83.33%)	ALDH2;ALDH3A1;ALDH3A2;...
Ovarian steroidogenesis	1.86	5.78e-3	41/51 (80.39%)	AKR1C3;HSD17B7;LDLR;...
Ascorbate and aldarate metabolism	1.85	6.01e-3	15/30 (50%)	ALDH2;ALDH3A2;UGT2B4;...
Cholesterol metabolism	1.85	5.51e-3	44/50 (88%)	LDLR;NPC2;LIPA;...
Valine, leucine and isoleucine degradation	1.85	5.08e-3	42/48 (87.5%)	HMGCS1;ALDH2;ALDH3A2;...
Folate biosynthesis	1.79	1.12e-2	23/26 (88.46%)	AKR1C3;AKR1B10;PAH;...
Butanoate metabolism	1.76	1.38e-2	23/28 (82.14%)	HMGCS1;AACS;ACAT2;...
Synthesis and degradation of ketone bodies	1.73	1.70e-2	9/10 (90%)	HMGCS1;ACAT2
Pentose and glucuronate interconversions	1.70	2.38e-2	17/34 (50%)	AKR1B10;CRYL1;UGT2B4;...
Complement and coagulation cascades	1.68	3.03e-2	76/85 (89.41%)	F5;SERPINA1;FGB;...
Renin-angiotensin system	1.66	3.35e-2	20/23 (86.96%)	AGT;MME;ACE2;...
Protein processing in endoplasmic reticulum	-1.72	4.46e-2	127/171 (74.27%)	RAD23A;MBTPS1;SEC61A1;...
African trypanosomiasis	-1.74	4.54e-2	32/37 (86.49%)	FAS;GNAQ;APOL1;...
DNA replication	-1.74	4.92e-2	34/36 (94.44%)	RFC2;MCM3;POLD2;...
Aminoacyl-tRNA biosynthesis	-1.76	4.33e-2	15/66 (22.73%)	GATC;FARS2;DARS2;...
Protein export	-1.78	4.10e-2	17/23 (73.91%)	SEC61A1;SEC61B;SRPRB;...
RNA transport	-1.82	2.79e-2	128/186 (68.82%)	NUP62;STRAP;POP1;...
Ribosome biogenesis in eukaryotes	-1.88	9.57e-3	52/108 (48.15%)	POP1;NOL6;CSNK2B;...
Ribosome	-1.92	8.97e-3	113/158 (71.52%)	RPS29;RPS5;RPL19;...
Prion disease	-1.93	1.20e-2	209/273 (76.56%)	PSMC1;MAPK10;ATP5F1C;...
Proteasome	-2.18	0.00e+0	44/46 (95.65%)	PSMC1;PSMB6;PSMA2;...
Spliceosome	-2.19	0.00e+0	101/150 (67.33%)	SNRNP40;RBM22;SNRPC;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H